Novavax, Inc. (NVAX) — closed signal from March 5, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 3, 2026.
Predicted vs. what happened
What happened
Reached 54% of the predicted growth at its peak, without hitting the target.
The thesis — published March 5, 2026
Novavax just reported surprise profit and stronger sales, and announced a deal with Pfizer that brings upfront cash and future royalties. That shifts the company toward earning steady licensing money instead of relying only on selling vaccines. The stock has been rising in a way that looks steady, but it swings a lot, so treat this as a short-term rebound idea and manage risk tightly.
Primary drivers
- Surprise profit and stronger sales attract new buyers
- Licensing deal with Pfizer improves near-term cash flow
- Price action shows steady post-news improvement, not a panic spike
- High biotech swings can quickly push price up or down
How it played out
NVAX: rebound helped, target was not reached
Lyra published NVAX on 2026-03-05 at $9.75 as a short-term rebound idea. The thesis expected 35% growth and pointed to surprise profit, stronger sales, a Pfizer licensing deal with upfront cash and future royalties, steadier post-news price action, and high biotech swings that could move the stock either way.
Inside the window, the stock rose but did not reach the $13.16 target. It peaked at $11.61 on 2026-05-27, a 19% gain, then ended at $10.20 on 2026-06-03. The thesis partially played out. The direction was right, but the move stayed below the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.